IP Library › Granted Patent US 12,209,318
Granted Patent B2
US 12,209,318 · App. 17/553,401 · Granted Jan 28, 2025

Methods, systems, and apparatuses for delivery of electrolysis products

Inventors: Boris Rubinsky (El Cerrito, CA); Paul Mikus (Coto de Caza, CA); Liel Rubinsky (El Cerrito, CA)
Assignee: RM2 TECHNOLOGY LLC
C25B1/26A61B18/02A61B18/04A61B18/12A61B18/1492A61M1/916A61M25/104A61N1/0502A61N1/32A61N1/325A61N1/327C25B9/17C25B11/04A61B2018/00333A61B2018/00404A61B2018/00434A61B2018/00452A61B2018/00464A61B2018/00482A61B2018/00517A61B2018/00547A61B2018/00577A61B2018/00613A61B2018/00827A61B2018/00892A61B2018/1425A61B2018/143A61B18/16A61M2025/105A61M2025/1052A61M2205/054A61M2205/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,209,318
App. No.
17/553,401
Granted
Jan 28, 2025
Kind
B2
Abstract

Example apparatuses and systems are disclosed for providing controlled delivery of electrolysis products to a site which may be used for treatment of infection and ablation of undesirable cells and tissue. A system disclosed may include a power supply, two electrodes, an aqueous matrix that may close the electric circuit between the electrodes at the treated site, and a controller. The controller may control the electrical circuit to induce a direct current through the electrodes and an aqueous matrix to produce electrolysis products. The duration and magnitude of the charge applied may determine the dose of the products applied to the treatment site. The composition of the electrodes and the aqueous matrix may be chosen to produce desired products. An apparatus is disclosed that may be in the form of a pad for applying to a wound. An apparatus is disclosed that may be used for treating internal tissue.

Claims (35)

1. A method for delivering electrolysis products to a site, the method comprising:

using a controller, generating an electrical signal indicative of a timing and dose of the electrolysis products, wherein the electrolysis products are configured to cause ablation;

providing the electrical signal to a device proximate the site;

applying a current proximate the site by the device responsive to the electrical signal;

causing a portion of aqueous matrix proximate the site to generate the electrolysis products proximate the site responsive to the current; and

controlling at least one of a magnitude or a duration of the current to modulate an amount of the electrolysis products.

2. The method of claim 1 , wherein the device comprises at least one electrode and an aqueous matrix, wherein the electrolysis products are generated in the aqueous matrix responsive to the electrical signal applying a current through the aqueous matrix.

3. The method of claim 2 , further comprising delivering a drug to the site, wherein the drug is included with the aqueous matrix.

4. The method of claim 2 , further comprising:

sensing a pH value in the aqueous matrix between the electrode and the site;

providing the pH value to the controller; and

adjusting the electrical signal responsive to the pH value.

5. The method of claim 4 , further comprising adding additional components to the aqueous matrix to adjust the pH if the pH value is outside a predetermined range.

6. The method of claim 2 , wherein the at least one electrode and the aqueous matrix are packaged for placement proximate the site.

7. The method of claim 1 , wherein the device comprises a pad, and wherein the method further comprises applying the pad to the site.

8. The method of claim 1 , wherein the device comprises a pad, and wherein the method further comprises implanting the pad proximate the site.

9. The method of claim 1 , wherein the device comprises one of a surface pad, luminal catheter, or a needle.

10. The method of claim 1 , wherein using the controller comprises accessing a memory storing electrical signal patterns suitable for particular doses and depths of electrolysis product delivery.

11. The method of claim 1 , wherein the site comprises a bed sore, a diabetic ulser, a burn, acne, a tumor, an abdominal surface, a nerve, a blood vessel surface, an intestinal surface, an esophageal surface, a urethra surface, a bladder surface, or a combination thereof.

12. The method of claim 1 , wherein the electrical signal is to control timing and magnitude of a current to produce the dose of the electrolysis products.

13. A method for delivering electrolysis products to a site, the method comprising:

passing a current through an aqueous matrix, wherein the aqueous matrix is configured to produce electrolysis products responsive to the current, wherein the electrolysis products are configured to cause ablation; and

modulating an amount of the electrolysis products produced by a portion of the aqueous matrix responsive to controlling at least one of a magnitude or a duration of the current applied to the portion of the aqueous matrix.

14. The method of claim 13 , further comprising generating the current by applying an electrical signal to at least one electrode.

15. The method of claim 14 , wherein the electrical signal is a pulsed electrical signal comprising one or more pulses.

16. The method of claim 14 , wherein the at least one electrode and the aqueous matrix are packaged for placement proximate the site.

17. The method of claim 13 , further comprising controlling a direction of flow of ions of the electrolysis by performing iontophoresis, electro osmosis, electrophoresis, or a combination thereof.

18. The method of claim 13 , further comprising removing depleted electrolysis products, ablated materials, or a combination thereof from the site.

19. The method of claim 18 , wherein the removing comprises applying a negative pressure to the site.

20. The method of claim 18 , wherein the removing is performed by a lumen of a catheter.

21. The method of claim 13 , wherein controlling at least one of the magnitude or the duration of the current comprises turning the current on and off.

22. The method of claim 13 , further comprising measuring a pH of the site.

23. The method of claim 22 , wherein the controlling at least one of the magnitude or the duration of the current is performed responsive the pH measured.

24. The method of claim 13 , wherein the current comprises a direct current.

25. The method of claim 13 , further comprising delivering the aqueous matrix to the site by injection, implantation, or a combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2021
From: RUBINSKY, BORIS; MIKUS, PAUL; RUBINSKY, LIEL
To: RM2 TECHNOLOGY LLC
Reel/Frame 058524/0735 →
Continuity (6)
Division 16219815 · Dec 13, 2018
Continuation 15036386
Provisional Application 61938623 · Feb 11, 2014
Provisional Application 61921084 · Dec 27, 2013
Provisional Application 61904142 · Nov 14, 2013
Related Publication 20220105256A1 · Apr 7, 2022
References Cited (117)
US 5389069A · Weaver et al. · 1995 [cited by applicant]
US 5468223A · Mir · 1995 [cited by applicant]
US 5911223A · Weaver et al. · 1999 [cited by applicant]
US 6300108B1 · Rubinsky et al. · 2001 [cited by applicant]
US 6366808B1 · Schroeppel et al. · 2002 [cited by applicant]
US 6403348B1 · Rubinsky et al. · 2002 [cited by applicant]
US 6767347B2 · Sharkey · 2004 [cited by examiner]
US 7113821B1 · Sun et al. · 2006 [cited by applicant]
US 7344533B2 · Pearson et al. · 2008 [cited by applicant]
US 7680543B2 · Azure · 2010 [cited by applicant]
US 7718409B2 · Rubinsky et al. · 2010 [cited by applicant]
US 7955827B2 · Rubinsky et al. · 2011 [cited by applicant]
US 8048067B2 · Davalos et al. · 2011 [cited by applicant]
US 8145316B2 · Deem et al. · 2012 [cited by applicant]
US 8282631B2 · Davalos et al. · 2012 [cited by applicant]
US 8849413B2 · Makdissi · 2014 [cited by applicant]
US 8926606B2 · Davalos et al. · 2015 [cited by applicant]
US 9005189B2 · Davalos et al. · 2015 [cited by applicant]
US 9283051B2 · Garcia et al. · 2016 [cited by applicant]
US 9700368B2 · Callas et al. · 2017 [cited by applicant]
US 9901735B1 · Lee et al. · 2018 [cited by applicant]
US 10154873B2 · Rubinsky et al. · 2018 [cited by applicant]
US 10390874B2 · Rubinsky et al. · 2019 [cited by applicant]
US 10939949B2 · Rubinsky et al. · 2021 [cited by applicant]
US 11123475B2 · Rubinsky et al. · 2021 [cited by applicant]
US 11260165B2 · Rubinsky et al. · 2022 [cited by applicant]
US 11857244B2 · Rubinsky et al. · 2024 [cited by applicant]
US 11866833B2 · Rubinsky et al. · 2024 [cited by applicant]
US 20010021868A1 · Herbst et al. · 2001 [cited by applicant]
US 20020010491A1 · Schoenbach et al. · 2002 [cited by applicant]
US 20020143365A1 · Herbst · 2002 [cited by applicant]
US 20030042134A1 · Tremblay et al. · 2003 [cited by applicant]
US 20040213698A1 · Tennakoon et al. · 2004 [cited by applicant]
US 20060116663A1 · Joshi et al. · 2006 [cited by applicant]
US 20060293731A1 · Rubinsky et al. · 2006 [cited by applicant]
US 20080167650A1 · Joshi et al. · 2008 [cited by applicant]
US 20090287208A1 · Rosemberg · 2009 [cited by applicant]
US 20100030211A1 · Davalos et al. · 2010 [cited by applicant]
US 20100036446A9 · Auge et al. · 2010 [cited by applicant]
US 20100168646A1 · Greenbaum et al. · 2010 [cited by applicant]
US 20100183745A1 · Rossi et al. · 2010 [cited by applicant]
US 20110106072A1 · Sundquist et al. · 2011 [cited by applicant]
US 20120059255A1 · Paul et al. · 2012 [cited by applicant]
US 20120071874A1 · Davalos et al. · 2012 [cited by applicant]
US 20120130369A1 · Cadossi et al. · 2012 [cited by applicant]
US 20120150173A1 · Joshi et al. · 2012 [cited by applicant]
US 20120220998A1 · Long et al. · 2012 [cited by applicant]
US 20130218157A1 · Callas et al. · 2013 [cited by applicant]
US 20140066913A1 · Sherman · 2014 [cited by applicant]
US 20140276767A1 · Brotz et al. · 2014 [cited by applicant]
US 20140316485A1 · Ackermann et al. · 2014 [cited by applicant]
US 20160184003A1 · Srimathveeravalli et al. · 2016 [cited by applicant]
US 20160287867A1 · Rubinsky et al. · 2016 [cited by applicant]
US 20160296269A1 · Rubinsky et al. · 2016 [cited by applicant]
US 20180193082A1 · Rubinsky et al. · 2018 [cited by applicant]
US 20190117291A1 · Rubinsky et al. · 2019 [cited by applicant]
US 20190357960A1 · Rubinsky et al. · 2019 [cited by applicant]
US 20210186592A1 · Rubinsky et al. · 2021 [cited by applicant]
US 20210220532A1 · Rubinsky et al. · 2021 [cited by applicant]
US 20210330371A1 · Günther et al. · 2021 [cited by applicant]
EP 2311522A1 · 2011 [cited by applicant]
EP 2425871A2 · 2012 [cited by applicant]
EP 1696812B1 · 2015 [cited by applicant]
WO 03103521A1 · 2003 [cited by applicant]
WO 2007070637A2 · 2007 [cited by applicant]
WO 2015021113A1 · 2015 [cited by applicant]
WO 2015073877A1 · 2015 [cited by applicant]
WO 2015073885A1 · 2015 [cited by applicant]
WO 2016178697A1 · 2016 [cited by applicant]
WO WO2017143269A1 · 2017 [cited by applicant]
WO WO2020051241A1 · 2020 [cited by applicant]
Extended European Search Report for Application No. EP19857135.8, mailed on Apr. 13, 2022, 07 pages. [cited by applicant]
Extended European Search Report for Application No. EP21212300.4, mailed on Apr. 25, 2022, 09 pages. [cited by applicant]
Lv Y., et al., “Molecular and Histological Study on the Effects of Electrolytic Electroporation on the Liver,” Bioelectrochemistry, Feb. 2019, vol. 125, pp. 79-89. [cited by applicant]
The Extended European Search Report dated Jan. 17, 2022 for European Patent Application No. 21212317.8. [cited by applicant]
Examination Report dated Mar. 19, 2018 for European Application No. 14862428.1. [cited by applicant]
Examination Report dated Mar. 19, 2018 for European Application No. 14862589.0. [cited by applicant]
International Search Report & Written Opinion dated Apr. 21, 2015 received for PCT/US2014/065794. [cited by applicant]
International Search Report and Written Opinion Received for PCT/US2014/065783 dated Mar. 18, 2015. [cited by applicant]
Office Action for CN Application No. 201580080597.8, dated May 7, 2020. [cited by applicant]
Office Action for EP Application No. 14862428.1, dated Dec. 16, 2020. [cited by applicant]
Office Action for EP Application No. 14862589.0, dated Dec. 11, 2020. [cited by applicant]
“International Search Report and Written Opinion received for PCT US2015/030628 dated Jan. 15, 2016”. [cited by applicant]
“Receipt of extended EP search report for application No. 14862428.1 dated May 10, 2017”. [cited by applicant]
“Receipt of extended EP search report for application No. 14862589.0 dated May 10, 2017”. [cited by applicant]
Ivorra, et al., “Electric Field Modulation in Tissue Electroporation With Electrolytic and Non-Electrolytic Additives”, Bioelectrochemistry 70, Feb. 2007, pp. 551-560. [cited by applicant]
Ivorra, et al., “In Vivo Electrical Impedance Measurements During and After Electroporation of Rat Liver”, Bioelectrochemistry 70, Oct. 2006, pp. 287-295. [cited by applicant]
Mir, et al., “Mechanisms of Electrochemotherapy”, Advanced Drug Delivery Reviews, vol. 35, No. 1, Jan. 1, 1999, XP055754391, Amsterdam, NL, pp. 107-118. [cited by applicant]
Czymek R., et al., “Electrochemical Treatment. An Investigation of Dose-response Relationships Using an Isolated Liver Perfusion Model,” Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology… [cited by applicant]
Davalos R.V., et al., “Tissue Ablation With Irreversible Electroporation,” Annals of Biomedical Engineering vol. 33 (2), Feb. 2005, pp. 223-231. [cited by applicant]
Edd Jon F., et al., “In Vivo Results of a New Focal Tissue Ablation Technique : Irreversible Electroporation,” IEEE Transactions on Bio-medical Engineering vol. 53 (5), Jul. 2006, pp. 1409-1415. [cited by applicant]
Fosh B.G., et al., “Electrolytic Ablation of the Rat Pancreas. A Feasibility Trial,” BMC Gastroenterology, vol. 1, 2001, pp. 1-5. [cited by applicant]
Gravante G., et al., “Experimental Application of Electrolysis in the Treatment of Liver and Pancreatic Tumours: Principles, Preclinical and Clinical Observations and Future Perspectives,” Surgical Oncology vol. 20 (2),… [cited by applicant]
Guenther E., et al., “Electrical Breakdown in Tissue Electroporation,” Biochemical and Biophysical Research Communications, vol. 467 (4), Nov. 2015, pp. 1-14. [cited by applicant]
Horwitz E.M., et al., “Definitions of Biochemical Failure That Best Predict Clinical Failure in Patients with Prostate Cancer Treated with External Beam Radiation Alone: a Multi-institutional Pooled Analysis,” The Journ… [cited by applicant]
Klein N., et al., “Single Exponential Decay Waveform; a Synergistic Combination of Electroporation and Electrolysis (E2) for Tissue Ablation,” Peer-Reviewed Journal, vol. 5. Apr. 2017, pp. 1-19. [cited by applicant]
Klein N., et al., “The Combination of Electroportation and Electrolysis (E2) Employing Different Electrode Arrays for Ablation of Large Tissue Volumes,” PLoS ONE vol. 14 (8), Aug. 2019, pp. 1-13. [cited by applicant]
Llyod M., et al., “Electrolysis—a New Method of Renal Ablation?,” BJU International, vol. 110 (Suppl 4), Dec. 2012, pp. 77-79. [cited by applicant]
MacLaren J. S., “Electrolysis in Prostate Enlargement,” Annals of Surgery vol. 9 (5), May 1889, pp. 347-350. [cited by applicant]
Martin R.C.G., et al., “Intra-Operative Anesthesia Management in Patients Undergoing Surgical Irreversible Electroporation of the Pancreas, Liver, Kidney, and Retroperitoneal Tumors,” Anesthesiology and Pain Medicine , … [cited by applicant]
Mir L.M., et al., “The Basis of Electrochemotherapy,” Methods in Molecular Medicine, vol. 37, 2000, pp. 99-117. [cited by applicant]
Neumann E., et al., “Electroporation and Electrofusion in Cell Biology,” Plenum Press, New York, 1989, pp. 1-435. [cited by applicant]
Neumann E., et al., “Gene Transfer Into Mouse Lyoma Cells by Electroporation in High Electric Fields,” The EMBO Journal 1(7), 1982, pp. 841-845. [cited by applicant]
Onik G., et al., “Irreversible Electroporation: First Patient Experience Focal Therapy of Prostate Cancer,” Irreversible Electroporation. Series in Biomedical Engineering Springer-Verlag Berlin Heidelberg, Berlin, Heide… [cited by applicant]
Phillips M., et al., “Combining Electrolysis and Electroporation for Tissue Ablation,” Technology in Cancer Research & Treatment, Aug. 2015, vol. 14 (4), pp. 395-410. [cited by applicant]
Phillips M., et al., “Modulating Electrolytic Tissue Ablation With Reversible Electroporation Pulses,” Technology, vol. 3 (1), 2015, pp. 45-53. [cited by applicant]
Phillips M., et al., “Tissue Ablation by a Synergistic Combination of Electroporation and Electrolysis Delivered by a Single Pulse,” Annals of Biomedical Engineering, vol. 44 (10), Oct. 2016, pp. 3144-3154. [cited by applicant]
Robertson G.S., et al., “Experimental Study of Electrolysis-induced Hepatic Necrosis,” The British Journal of Surgery, Sep. 1998, vol. 85 (9), pp. 1212-1216. [cited by applicant]
Rubinsky B., et al., “Irreversible Electroporation: A New Ablation Modality—clinical Implications,” Technology in Cancer Research & Treatment, Feb. 2007, vol. 6 (1), pp. 37-48. [cited by applicant]
Rubinsky B., et al., “Minimally Invasive, Non-Thermal Tissue Ablation with a Single Exponential Decay Electrolytic Electroporation Waveform,” Journal of Translational Medicine and Research, vol. 21 (4), 2016, pp. 247-25… [cited by applicant]
Rubinsky L., et al., “Electrolytic Effects During Tissue Ablation by Electroporation,” Technology in Cancer Research & Treatment, Oct. 2016, vol. 15(5), pp. 1-9. [cited by applicant]
Scheffer H., et al., “Irreversible Electroporation for Colorectal Liver Metastases ,” Techniques in Vascular and Interventional Radiology, Sep. 2015, vol. 18 (3), pp. 159-169. [cited by applicant]
Stehling K.M., et al., “Synergistic Combination of Electrolysis and Electroporation for Tissue Ablation,” PloS One, vol. 11 (2), 2016, pp. 1-23. [cited by applicant]
Tasu J.P., et al., “Irreversible Electroporation for Locally Advanced Pancreatic Cancer: Where Do We Stand in 2017?,” Pancreas, Mar. 2017, vol. 46(3), pp. 283-287. [cited by applicant]
Weaver J.C. and Chizmadzhev Y.A., “Theory of Electroporation: A Review,” Bioelectrochemistry and Bioenergetics, Mar. 1996, vol. 41 (2), pp. 135-160. [cited by applicant]
Denet A., et al., “Transdermal Delivery of Timolol by Electroporation Through Human Skin,” Journal of Controlled Release, Mar. 2003, vol. 88(2), pp. 253-262. [cited by applicant]
Saulis G., et al., “Changes of the Solution PH Due to Exposure by High-voltage Electric Pulses,” Bioelectrochemistry, Sep. 2005, vol. 67(1), pp. 101-108. [cited by applicant]
Cited By (1)
US 12,564,436